Posts

Three European biopharma firms are coming together to create one company with a mission to combat antimicrobial resistance (AMR). The new company, Aurobac Therapeutics SAS, was founded by Germany’s Boehringer Ingelheim and Evotec SE, along with France’s bioMérieux.

French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its medicines worldwide.

The agency’s decision came after researchers found cases of drug-induced liver injury in some patients.

French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for a 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.

Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said. The so-called bivalent vaccine targets the Beta variant – first identified in South Africa – as well as the original Wuhan strain of the virus.

A bipartisan bill introduced by the leaders of the Senate Diabetes Caucus aims to curb the pricing of life-saving insulin by capping monthly co-pays for diabetics who use both commercial insurance plans, as well as the government-backed Medicare.

Although a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe — Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca-Oxford — a number of companies are continuing to develop vaccines in hopes they can be used as booster shots. 

Sanofi said an upgraded version of the COVID-19 vaccine candidate the French drugmaker is developing with GSK showed potential in two trials to protect against the virus’s main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc.’s anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.

The U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.